Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 April 2021 | Story NONSINDISO QWABE | Photo Supplied
LLB graduate Tshepang Mahlatsi

 
‘Be loyal to your calling and the universe will locate you.’ This slogan is the mantra that University of the Free State LLM student, Tshepang Mahlatsi, lives by. It is also this slogan that carried him through a tumultuous journey during the pursuit of his LLB degree, which he received during the Bloemfontein Campus graduation ceremony on 19 April. 

Mahlatsi began his LLB degree in 2014, but he had to take a break from his academics in 2016 after being clinically diagnosed with depression. He obtained his qualification in 2020. Mahlatsi said 2016 was a year that started on a high note for him as a third-year Law student and newly elected prime for Tswelopele residence, but quickly took a downward dive when he found himself overwhelmed by leadership demands – coupled with the simultaneous loss of loved ones and constant academic pressure. It ultimately led to a breakdown, forcing him to put his studies on hold. "I am graduating with my LLB after life-changing events in my undergraduate years – from student politics, depression, and PTSD, to starting a mental-health organisation and using both CUADS and Kovsie Counselling support services to come back to ‘normalcy’.”

He said the year-long break from his studies left him feeling discouraged as he watched his peers and classmates progress and graduate. "It was the most difficult thing to do to remind myself that I wasn't stupid." 

"This journey exposed a lot about myself; it exposed that with determination and resilience, you can achieve what you set out to achieve. I had to persevere not because I wanted to, but because my family has never seen a graduate. I was doing this for them; to give them something they've never had,” he said. 

UFS support services can save lives 

Mahlatsi would like more students to make use of the UFS support services and not crumble under mental-health problems. "I hope to inspire students to use their support services and not be ashamed – services such as CUADS and Student Counselling and Development. I hope to inspire student leaders and students to realise that you can be a well-rounded student and still have challenges, but eventually, success awaits us all."

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept